AA
OLMA icon

ALPS Advisors’s Olema Pharmaceuticals OLMA Stock Holding History

ALPS Advisors’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$955K Sell
64,035
-557
-0.9% -$12.4K ﹤0.01% 591
2025
Q4 		$1.61M Buy
64,592
+32,082
+99% +$571K 0.01% 432
2025
Q3 		$318K Sell
32,510
-4,400
-12% -$26.4K ﹤0.01% 949
2025
Q2 		$157K Sell
36,910
-13,574
-27% -$60.5K ﹤0.01% 1016
2025
Q1 		$190K Buy
50,484
+4,149
+9% +$20.9K ﹤0.01% 964
2024
Q4 		$270K Buy
46,335
+644
+1% +$6.43K ﹤0.01% 949
2024
Q3 		$546K Buy
45,691
+2,039
+5% +$26.1K ﹤0.01% 594
2024
Q2 		$472K Buy
43,652
+4,791
+12% +$52K ﹤0.01% 589
2024
Q1 		$440K Buy
38,861
+698
+2% +$9.01K ﹤0.01% 611
2023
Q4 		$535K Buy
+38,163
New +$513K ﹤0.01% 594

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

ALPS Advisors's OLMA Position: Q1 2026 in Review

ALPS Advisors reduced its Olema Pharmaceuticals (OLMA) stake by 0.86% in Q1 2026, selling an estimated $12.4K and leaving 64,035 shares worth $955K. The position accounts for ﹤0.01% of the portfolio, ranked #591.

ALPS Advisors first reported a position in OLMA in Q4 2023 and has held it in 10 quarters since. The position peaked at $1.61M in Q4 2025. 195 funds tracked by Wall St. Rank hold OLMA as of Q1 2026.

  • ALPS Advisors held 64,035 shares of Olema Pharmaceuticals worth $955K as of Q1 2026.
  • ALPS Advisors sold 557 Olema Pharmaceuticals shares in Q1 2026, an estimated $12.4K.
  • Olema Pharmaceuticals made up ﹤0.01% of ALPS Advisors's portfolio in Q1 2026, its #591 holding.
  • ALPS Advisors first reported a position in Olema Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
  • ALPS Advisors's Olema Pharmaceuticals position peaked at $1.61M in Q4 2025.
  • 195 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2026.

Based on ALPS Advisors's 13F filing for Q1 2026, filed 8 May 2026.